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Abstract
Background: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular
carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM).
Methods: Nine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of
the lesion was 32 mm (range: 15–74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system.
Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400,
and 800 s/mm2. The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion
coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and
at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using
modified RECIST. IVIM parameters of the treatment responders and non-responders were compared.
Results: The DC of responders at baseline was significantly higher than that of the non-responders. The
sensitivity and specificity, when a DC of 0.8 (10−3 mm2/s) or higher was considered to be a responder, were
100 % and 67 %, respectively. No significant differences were found in the other parameters between the
responders and the non-responders. All IVIM parameters of the responders and non-responders did not
change significantly after treatment.
Conclusion: The DC before treatment may be a useful parameter for predicting the therapeutic outcome of
sorafenib for advanced HCC.
Keywords: Sorafenib, Hepatocellular carcinoma, Intravoxel incoherent motion, Biomarker, Diffusion-weighted
imaging
Background
The multikinase inhibitor sorafenib was reported to pro-
long the median survival and time to progression of
patients with advanced hepatocellular carcinoma (HCC)
[1]. Sorafenib inhibits tumor-cell proliferation and tumor
angiogenesis [2]. This drug prolongs the stable state of
HCC by reducing blood flow to the tumor and by in-
creasing tumor-cell apoptosis, rather than by decreasing
tumor size [1]. However, it was reported that the thera-
peutic effect of sorafenib could not be accurately evalu-
ated using the Response Evaluation Criteria in Solid
Tumors (RECIST) [3], which is conventionally used.
Therefore, it has been proposed that the modified
RECIST, including the effect on blood flow is more use-
ful for the evaluation of the therapeutic outcomes of
cancers [4, 5].
On the other hand, other studies have concluded that
diffusion-weighted imaging (DWI) was useful for the
evaluation of the therapeutic outcomes of advanced
HCC, and did not require data on arterial blood flow in
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the lesion [6–8]. Furthermore, it has been proposed that
DWI is effective for evaluating the therapeutic outcomes
of chemotherapy or radiation therapy on other types of
tumors [9–11]. DW images are obtained by visualizing
the motion of water molecules randomly using MRI.
Because DWI is sensitive to changes of intracellular
substances and cell membranes, it is often used for
therapeutic monitoring [10]. In previous reports, the
bleeding or necrosis of tumors increased diffusion
values in the responder group [6].
Lewin et al. reported the usefulness of intravoxel inco-
herent motion (IVIM) for the evaluation of the thera-
peutic outcome of sorafenib [7]. It is possible to obtain
the true diffusion coefficient reflecting cell density and
the perfusion fraction reflecting the microcirculation of
tumors using IVIM. Therefore, IVIM may reflect tumor
necrosis and neovascular inhibition resulting from the
therapeutic effect of sorafenib. Furthermore, IVIM may
be able to predict therapeutic outcomes before treat-
ment. Because sorafenib treatment frequently causes side
effects and is expensive, it is often difficult for patients
to maintain medication compliance. Therefore, it would
be highly beneficial if therapeutic efficacy could be deter-
mined at an early stage.
Here we reported a pilot study on the efficacy of IVIM
for the evaluation of the therapeutic effects and early
treatment effects of sorafenib for advanced HCC.
Methods
The study was approved by the ethics committee of our
institution, and written informed consent was obtained
from all the patients who participated in this study.
Subjects
Thirty-seven patients with HCC were examined from
July 2009 to January 2012. The study inclusion criteria
were patients receiving sorafenib therapy, Barcelona
Clinic Liver Cancer stage of B or C, and no contraindi-
cations to MRI. This prospective study was part of an
assessment of the efficacy of radiological analysis to pre-
dict therapeutic outcomes and prognostic expectations.
Radiological assessment included contrast-enhanced
ultrasound and MRI. Some patients refused all 3 MRI
examinations or carelessly forgot to undergo an examin-
ation, and 10 patients remained in the study. Of the 10
patients who underwent liver MRI, 1 was excluded
because of poor image quality due to artifacts. The final
study population included 9 patients with HCC. The
largest and previously untreated lesion in each patient
was analyzed. Contrast-enhanced ultrasound (US) was
performed to evaluate the presence of arterial blood flow
in the lesion before baseline MRI. A diagnostic US sys-
tem (SSA-790A, Aplio XG; Toshiba Medical Systems
Corporation, Otawara, Japan) with a 3.75-MHz convex
transducer was used. A second-generation US contrast
agent (Sonazoid; Daiichi-Sankyo, Tokyo, Japan) was
injected as a 0.5-mL bolus into an antecubital vein
followed by a 10-mL saline flush at 1 mL/s.
MRI Protocol
MR imaging was performed with a 1.5-Tesla scanner 32-
channel coil system (Avanto, Siemens Medical Systems,
Erlangen, Germany) with a peak slew rate of 200 T/m/s.
MRI sequences were subjected to T1-weighted imaging,
T2-weighted imaging, and DWI.
T1-weighted images were acquired using the following
sequence parameters: gradient echo sequence; repetition
time: 125 ms; dual echo time; opposed phase: 2.38 ms;
in phase: 4.76 ms; flip angle: 75°; matrix size: 320 × 126;
field of view: 400 × 454 mm; slice thickness: 5 mm; re-
ceiver bandwidth: 470 Hz/pixel; acquisition time: 13 s.
T2-weighted images were acquired during breath-
holding using the following sequence parameters: turbo
spin-echo sequence; repetition time: 3,980 ms; echo
time: 95 ms; flip angle: 150°; matrix size: 320 × 135; field
of view: 400 × 454 mm; slice thickness: 5 mm; receiver
bandwidth: 260 Hz/pixel; acquisition time: 20 s. DW im-
ages were acquired using the following sequence param-
eters: spin echo based echo-planar imaging; repetition
time: 1,200 ms; echo time: 63 ms; flip angle: 90°; matrix
size: 110 × 110; field of view: 400 × 454 mm; 1 averaging;
slice thickness: 5 mm; receiver bandwidth: 921 Hz/pixel;
fat suppression; spectral pre-saturation with inversion
recovery; acquisition time: 20 s; b-values: 0, 50, 100, 150,
200, 400, and 800 s/mm2. DWI was performed during
breath-holding.
Tumors were evaluated by MRI at baseline, and at 1,
2, and 4 weeks after sorafenib treatment.
Follow-up
CT or MRI was performed before the start of sorafenib
therapy, at 1 month and every 2 months thereafter. Dy-
namic CT was performed using either a 16-detector row
or 64-detector row CT scanner. Iohexol 300 (Omnipaque
300, Daiichi-Sankyo) was injected over 30 s [12]. The
amount of contrast agent used was 600 mgI/kg [13]. The
arterial-dominant phase was obtained using a monitor
scan; following this the portal-dominant phase and equilib-
rium phase were obtained. Dynamic MRI was performed
using gadoterate meglumine (Magnescope, Guerbet) or
gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic
acid (Primovist, Bayer). Magnescope (0.1 mmol/kg) was
injected at 2 mL/s and Primovist (0.025 mmol/kg) was
injected at 1 mL/s. Monitor scan was performed by first
obtaining the arterial-dominant phase and then the portal-
dominant and equilibrium phases. We evaluated the cura-
tive effects using dynamic CT or dynamic MRI at baseline,
and after 1, 2, and 4 weeks of sorafenib treatment. We
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evaluated the curative effect by modified RECIST [3].
Curative effects were divided into 2 groups, namely,
responders (complete response, partial response, and stable
disease) and non-responders (progressive disease).
Changes in signal strength
Changes in signal strength of the lesions on T1-
weighted and T2-weighted imaging were evaluated by 2
radiologists who had 2 and 24 years of experience, by
consensus reading. They compared the signal strengths
and homogeneity of the lesions at baseline with those
after 1, 2, and 4 weeks of sorafenib treatment, and they
recorded whether a difference was present or absent.
Calculation of IVIM parameters
The IVIM model is considered to provide the pure mo-
lecular diffusion (D) separately from the blood microcir-
culation (proportion of blood microcirculation [PF] and
pseudo-diffusion coefficient [D*]), when multiple b-
values are obtained, from low b-values (<200 s/mm2) to
high b-values (>200 s/mm2) [14]. IVIM parameters were
calculated using the following formula [14]:
Sb=S0 ¼ f  exp‐ D  þDð Þ  bf g þ 1− fð Þ  −D bf g
ð1Þ
D: true diffusion coefficient (DC); D*: pseudo-diffusion
coefficient; f: perfusion fraction (PF); Sb, S0: signal inten-
sity with and without the application of the diffusion
gradient, respectively.
The 2-step fitting procedure was adopted to determine
PF, D, and D*, required because of the high dispersion and
limited sampling of DWI signals at low b-values (b <
200 s/mm2). Values of D were estimated from signal in-
tensity data at high b-values (b > 200 s/mm2). Considering
that D* is significantly greater than D, its effect on signal
decay can be neglected for b-values greater than 200 s/
mm2. Eq. (1) can be simplified and the D can be obtained
using only b-values equal to or greater than 200 s/mm2,
with the following simple linear fit equation:
Sb=S0 ¼ exp −bDð Þ ð2Þ
After determination of the D-value using Eq. (2), PF
and D* can be processed using a nonlinear least squares
estimate based on Eq. (1). The apparent diffusion coeffi-
cient (ADC) was obtained using all b-values by simple
linear fitting as in Eq. (2). IVIM parameters were calcu-
lated using freely available software at the website
(http://yamarad.umin.ne.jp/ivim/simplex.html). The IVIM
data were constrained as follows: 0 < PF < 1, 0 < D <D* <
1 mm2/s, 0 < ADC.
Statistical analysis
IVIM parameters were expressed as means ± standard
deviations. Changes in the signal strengths of T1-
weighted and T2-weighted images of the responder
group and the non-responder group were statistically
analyzed using the chi-squared test. The differences in
IVIM parameters between the responder group and the
non-responder group were statistically analyzed using
the Mann–Whitney U test and Fisher exact test. In
addition, differences in IVIM parameters between pre-
treatment and post-treatment were evaluated using the
Friedman test. A p-value less than 0.05 was considered
to indicate a statistically significant difference between 2
groups. When a significant difference was observed, the
cut-off value was determined by receiver operating char-
acteristic analysis, and then sensitivity and specificity
were calculated. All statistical analyses were performed
using SPSS statistics software (version 22, SPSS) for
Microsoft windows.
Results
Six patients (67 %) had at least 1 non-permissible value
of PF or D* within the 4 consecutive examinations. Six
patients were classified as responders (Complete Re-
sponse: 1; Stable Disease: 5), and 3 patients were classi-
fied as non-responders. Detailed information of the
patients is described in Table 1. The sizes of the lesions
did not significantly change in both the responder and
non-responder group, although the lesions in the non-
responder group tended to increase in size. There were
no remarkable signal changes between before and after
treatment on T1-weighted and T2-weighted imaging in
both the responders and the non-responders.
The IVIM parameters of ADC, D, D*, and PF in the
responders and non-responders at baseline, and after 1,
2, and 4 weeks of treatment are shown in Table 2 and
Figs. 1, 2, 3 and 4.
The ADCs of the responders at baseline, and after 1, 2,
and 4 weeks of treatment were 1.06 ± 0.21, 0.98 ± 0.25,
0.93 ± 0.16, and 0.84 ± 0.11 (10−3 mm2/s), respectively,
and of the non-responders were 0.85 ± 0.04, 1.00 ± 0.05,
0.88 ± 0.33, and 0.92 ± 0.33 (10−3 mm2/s), respectively. A
statistically significant difference was not detected be-
tween the responders and the non-responders. (p =
0.095, 0.548, 1.00, and 0.905 at baseline, and after 1, 2,
and 4 weeks of treatment, respectively). The DC of the
responders at baseline, and after 1, 2, and 4 weeks of
treatment were 1.04 ± 0.23, 0.99 ± 0.38, 0.90 ± 0.25, and
0.80 ± 0.08 (10−3 mm2/s), respectively, and of the non-
responders were 0.78 ± 0.06, 0.94 ± 0.20, 0.84 ± 0.32, and
0.83 ± 0.23 (10−3 mm2/s), respectively. The DC of re-
sponders at baseline was significantly higher than that of
the non-responders (p = 0.048, 1.00, 0.905, and 0.714 at
baseline, and after 1, 2, and 4 weeks of treatment,
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respectively). The sensitivity and specificity, when a DC
of 0.8 (10−3 mm2/s) or higher was considered to be a re-
sponder, were 100 % (95 % CI: 83, 100) and 67 % (95 %
CI: 27.2, 66.7), respectively. The D*s of responders at
baseline, and after 1, 2, and 4 weeks of treatment were
228 ± 392, 452 ± 376, 470 ± 441, and 321 ± 389 (10−3
mm2/s), respectively, and of the non-responders were
317 ± 274, 657 ± 555, 676 ± 272, and 323 ± 276 (10−3
mm2/s), respectively. There were no significant differ-
ences between the 2 groups (p = 0.381, 0.714, 0.548, and
1.00 at baseline, and after 1, 2, and 4 weeks of treatment,
respectively). The PFs of the responders at baseline, and
after 1, 2, and 4 weeks of treatment were 0.20 ± 0.28,
0.06 ± 0.04, 0.12 ± 0.11, and 0.08 ± 0.06 (10−3 mm2/s),
respectively, and of the non-responders were 0.10 ± 0.08,
0.06 ± 0.04, 0.07 ± 0.08, and 0.10 ± 0.12 (10−3 mm2/s), re-
spectively. There were no significant differences between
the 2 groups (p = 0.905, 1.00, 0.905, and 1.00 at baseline,
and after 1, 2, and 4 weeks of treatment, respectively).
Regarding changes in each parameter with treatment,
the responders showed a decrease in the ADC and DC,
whereas the non-responders did not. However, these
changes were not statistically significant (p = 0.102 and
0.719 for ADC, and p = 0.100 and 0.334 for DC in the
responder and non-responder group, respectively). The
responders showed a decrease in PF at 1 week after
treatment compared with the baseline, but this was
not statistically significant (p = 0.978 and 0.801 in the
responder and non-responder group, respectively).
Furthermore, we did not observe a statistically significant
difference in D* (p = 0.261 and 0.801 in the responder and
non-responder group, respectively).
Discussion
In our study, DC values in the responder group were
significantly higher than those in the non-responder
group at baseline, suggesting that it is possible to predict
therapeutic outcome before the initiation of treatment.
In addition, at baseline, ADC values of the responder
group were higher than those of the non-responder
group, although this difference was not significant. Woo
et al. reported that the histological grade of HCC corre-
lated more strongly with the DC than the ADC [15]. Be-
cause the ADC includes not only pure diffusion, but also
perfusion as compared with DC, its interpretation may
be complicated. They reported that the DC of patients
with high-grade HCC was significantly lower than that
of patients with low-grade HCC. It was also reported
that favorable treatment results were obtained with so-
rafenib in patients with histologically well-differentiated
tumors. Furthermore, the degrees of differentiation of
tumors were shown to correlate with their expression
levels of vascular endothelial growth factor (VEGF),
i.e., high expression levels of VEGF indicated well-
differentiated HCC [16]. We believe that the results
of our present study reflect the results of this previ-
ous study [17].
Table 2 IVIM parameters of responders and non-responders
ADC (10−3 mm2/s) DC (10−3 mm2/s) D* (10−3 mm2/s) PF
Responder Non-responder Responder Non-responder Responder Non-responder Responder Non-responder
Baseline 1.06 ± 0.21 0.85 ± 0.04 1.04 ± 0.23 0.78 ± 0.06 228 ± 392 317 ± 274 0.20 ± 0.28 0.10 ± 0.08
1 week 0.98 ± 0.25 1.00 ± 0.05 0.99 ± 0.38 0.94 ± 0.20 452 ± 376 657 ± 555 0.06 ± 0.04 0.06 ± 0.04
2 weeks 0.93 ± 0.16 0.88 ± 0.33 0.90 ± 0.25 0.84 ± 0.32 470 ± 441 676 ± 272 0.12 ± 0.11 0.07 ± 0.08
4 weeks 0.84 ± 0.11 0.92 ± 0.33 0.80 ± 0.08 0.83 ± 0.23 321 ± 389 323 ± 276 0.08 ± 0.06 0.10 ± 0.12
ADC apparent diffusion coefficient, DC true diffusion coefficient, D* pseudo-diffusion coefficient, PF perfusion fraction
Table 1 Patient characteristics
Responder Non-responder





Hepatitis B 0 1








Tumor size (mm; mean ± SD)
Baseline 30.7 ± 22.1 33.5 ± 14.1
1 week 30.3 ± 21.8 35.0 ± 14.6
2 weeks 31.0 ± 20.7 37.3 ± 16.7
4 weeks 31.5 ± 19.4 38.5 ± 15.9
Treatment
Sorafenib (initial dose) 200 mg twice daily 200 mg twice daily
BCLC stage Barcelona Clinic Liver Cancer stage, TAE transcatheter arterial
embolization, TACE transcatheter arterial chemoembolization, RFA
radiofrequency ablation therapy
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The DC and ADC values showed a decrease in the re-
sponders with treatment, but this was not significant,
and is consistent with previous reports [6, 7]. Schraml et
al. reported that these changes are caused by bleeding
[5]; however, we did not detect any bleeding, consistent
with the report by Lewin et al. [7]. They reported that
the ADC was increased at 2–3 months after treatment
because of necrotic changes. We did not find any obvi-
ous changes on the images, such as those reflecting ne-
crosis, because we only evaluated the patients up to
4 weeks of treatment.
We observed a decrease in the PF after 1 week of
treatment in the responders. On the other hand, Lewin
et al. reported an increase in the PF after 2 weeks of
treatment [7]. Because sorafenib inhibits tumor angio-
genesis, it causes the disruption and normalization of
tumor vessels [18]. This normalization of tumor blood
vessels suppresses permeability, resulting in a decrease
in the pressure of the tumor tissue. Lewin et al. de-
scribed the cause of the increased PF as an increase in
the perfusion rate by normalization of tumor blood ves-
sels. In our present study, the factor that differed from
the study of Lewin et al. was the scanning periods. In
addition, the method of calculation of the PFs was also
different. It has been reported that PFs and D*s have
poor reproducibility [19]. Therefore, it may be useful to
scan many low b-values to obtain a stable PF value. We
Fig. 3 Pseudo-diffusion coefficients of the responders and non-
responders at baseline, and after 1, 2, and 4 weeks of treatment.
No significant changes or differences were observed between
the 2 groups
Fig. 4 Perfusion fractions of the responders and non-responders at
baseline, and after 1, 2, and 4 weeks of sorafenib treatment. No
significant changes or differences were observed between the
2 groups
Fig. 1 Apparent diffusion coefficients (ADCs) of the responders and
non-responders at baseline, and after 1, 2, and 4 weeks of sorafenib
treatment. At baseline, ADC values in the responder group were
higher than those in the non-responder group; however, the difference
was not statistically significant
Fig. 2 True diffusion coefficients (DCs) of the responders and
non-responders at baseline, and after 1, 2, and 4 weeks of sorafenib
treatment. DC values of the responder group were significantly higher
than those of the non-responder group at baseline
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measured a total of 7 b-values (0, 50, 100, 150, 200, 400,
and 800 s/mm2), whereas Lewin et al. measured a total
of 4 (0, 200, 400, and 800 s/mm2). In this regard, our re-
sults may be more reliable.
Our study has several limitations. The first limitation
is the small number of patients studied. High sensitivity
and specificity of differentiation between responders and
non-responders was found in our study. However, these
results might be an overestimation because of the small
number of subjects. The study should be repeated with a
larger number of patients in the future. The second limi-
tation is that some cases showed poor fitting of IVIM.
When such cases occurred, outliers were removed from
the measurements. In other studies, scanning by the ap-
propriate b-values and other techniques, such as Bayesian
fitting, were used to obtain better fitting [20, 21]. In the
future, other methods to improve the fitting should be
tested. The third limitation is the lack of evaluation of
reproducibility. A previous report stated that D* and PF
showed poor reproducibility, whereas DC showed rela-
tively high reproducibility [19]. Therefore, we believe that
the conclusion of our study is reliable. The fourth limita-
tion is that we used breath-holding DWI. This technique
is faster than respiratory-triggered DWI but has the prob-
lem of a lower signal-to-noise ratio. However, Kim et al.
reported that ADCs calculated from breath-holding DWI
were more reproducible than those from respiratory-
triggered DWI [22]. Furthermore, respiratory-triggered
DWI requires longer acquisition times, and is prone
to misregistration, potentially leading to an inaccurate
ADC map [23]. Therefore, we believe that the breath-
holding technique was adequate for performing routine
examinations.
Conclusions
In conclusion, our results suggest that the DC obtained
by IVIM MRI may be useful as a biomarker for predicting
the therapeutic effects of sorafenib for HCC.
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